The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia

Chadi Nabhan, Neil Elliot Kay

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refractory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We review studies that led to ofatumumab's approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalClinical Medicine Insights: Oncology
Volume5
DOIs
StatePublished - 2011

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Antibodies, Monoclonal, Humanized
Anti-Idiotypic Antibodies
ofatumumab
Clinical Trials
Drug Therapy
Cell Line
Survival

Keywords

  • Anti-CD20
  • CLL
  • Monoclonal antibodies
  • Ofatumumab
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. / Nabhan, Chadi; Kay, Neil Elliot.

In: Clinical Medicine Insights: Oncology, Vol. 5, 2011, p. 45-53.

Research output: Contribution to journalArticle

@article{edbf615892b840ffaf76d4b3fc085d25,
title = "The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia",
abstract = "The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refractory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We review studies that led to ofatumumab's approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent.",
keywords = "Anti-CD20, CLL, Monoclonal antibodies, Ofatumumab, Targeted therapy",
author = "Chadi Nabhan and Kay, {Neil Elliot}",
year = "2011",
doi = "10.4137/CMO.S4087",
language = "English (US)",
volume = "5",
pages = "45--53",
journal = "Clinical Medicine Insights: Oncology",
issn = "1179-5549",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia

AU - Nabhan, Chadi

AU - Kay, Neil Elliot

PY - 2011

Y1 - 2011

N2 - The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refractory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We review studies that led to ofatumumab's approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent.

AB - The treatment of chronic lymphocytic leukemia (CLL) has evolved over the past decade. Our better understanding of disease biology and risk stratification has allowed delivering more effective therapies. In fact, front-line chemoimmunotherapy has demonstrated improvement in overall survival when compared to chemotherapy in randomized studies. Yet, treatment of relapsed CLL remains challenging and few agents are effective in that setting. Ofatumumab (Ofa) is a humanized monoclonal antibody targeted against CD20 with demonstrable activity in rituximab-resistant CLL cell lines. This agent was recently approved for the treatment of relapsed/refractory CLL patients who have failed fludarabine and alemtuzumab. In this review, we provide a historical perspective on approaches to CLL as front-line and in the relapsed setting. We further summarize novel anti-CD20 antibodies with specific emphasis on ofa. We review studies that led to ofatumumab's approval including pre-clinical data, trials using ofa in combination therapies, and adverse events/toxicities reported with this agent.

KW - Anti-CD20

KW - CLL

KW - Monoclonal antibodies

KW - Ofatumumab

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=79958057037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958057037&partnerID=8YFLogxK

U2 - 10.4137/CMO.S4087

DO - 10.4137/CMO.S4087

M3 - Article

C2 - 21499555

AN - SCOPUS:79958057037

VL - 5

SP - 45

EP - 53

JO - Clinical Medicine Insights: Oncology

JF - Clinical Medicine Insights: Oncology

SN - 1179-5549

ER -